Aspenbio Pharma (APPY) 0.45 $APPY
Venaxis Business Update
PR Newswire - Thu Feb 12, 8:00AM CST
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1® Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced that the Company will host an investor conference call to discuss business matters, including the recent FDA "Not Substantially Equivalent" response, on February 13, 2015, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 0.45 (-0.01)
INVESTOR ALERT: Investigation on Behalf of Investors of Venaxis, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Feb 10, 6:02PM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. ("Venaxis" or the "Company"
(NASDAQ:APPY) concerning possible violations of federal securities laws. The investigation is focused on the Company's operations and financial prospects.
APPY: 0.45 (-0.01)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Venaxis, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Feb 10, 12:43PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of Venaxis, Inc. ("Venaxis" or the "Company" (Nasdaq: APPY) securities during the period between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until April 3, 2015 to seek appointment as lead plaintiff.
APPY: 0.45 (-0.01)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Mon Feb 09, 8:11AM CST
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
XLS: 24.15 (+0.04), ADVS: 44.18 (+0.20), APPY: 0.45 (-0.01), MOV: 25.26 (-0.17), ENTR: 2.92 (unch), HLSS: 16.15 (-0.14), BABA: 89.05 (+1.95)
APPY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Venaxis, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of April 3, 2015 -- APPY
GlobeNewswire - Wed Feb 04, 1:16PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company" (Nasdaq:APPY) securities between March 13, 2014 and January 28, 2015.
APPY: 0.45 (-0.01)
Robbins Arroyo LLP: Venaxis, Inc. (APPY) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Tue Feb 03, 7:18PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Venaxis, Inc. (Nasdaq:APPY) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Colorado. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between March 13, 2014 and January 28, 2015. Venaxis develops and commercializes products for unmet diagnostic and therapeutic needs.
APPY: 0.45 (-0.01)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in Venaxis, Inc. (APPY) to Contact the Firm
Marketwired - Tue Feb 03, 3:00PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Venaxis, Inc. ("Venaxis" or the "Company" (NASDAQ: APPY) of the April 3, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Venaxis and certain officers of the Company.
APPY: 0.45 (-0.01)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Venaxis, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- APPY
GlobeNewswire - Tue Feb 03, 12:53PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of Venaxis, Inc. ("Venaxis" or the "Company" (Nasdaq:APPY) securities during the period between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until April 3, 2015 to seek appointment as lead plaintiff.
APPY: 0.45 (-0.01)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Venaxis, Inc. and Certain Officers -- APPY
GlobeNewswire - Mon Feb 02, 6:45PM CST
Pomerantz LLP has filed a class action lawsuit against Venaxis, Inc. ("Venaxis" or the "Company" (Nasdaq:APPY) and certain of its officers. The class action, filed in United States District Court, The District of Colorado, and docketed under 15-cv-00222, is on behalf of a class consisting of all persons or entities who purchased Venaxis securities between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
APPY: 0.45 (-0.01)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 29, 5:14PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), PSTI: 2.91 (+0.01), APPY: 0.45 (-0.01), NVC.TO: 11.27 (-0.23), GEVO: 0.23 (+0.03), PSTB: 6.94 (+0.04), OVLY: 10.65 (-0.05), PFMT: 6.02 (-0.02), BWINB: 23.41 (+0.01), AMIC: 10.75 (-0.10), APRI: 1.84 (-0.08), BWINA: 23.45 (-0.79), INOD: 2.78 (-0.02), XNCR: 15.47 (-0.22), FBSS: 17.59 (-0.11), NVCN: 9.08 (-0.17)
INVESTOR ALERT: Investigation of Venaxis, Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Thu Jan 29, 3:35PM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. ("Venaxis" or the "Company" (NASDAQ:APPY) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Venaxis concerning the Company's operations and financial prospects.
APPY: 0.45 (-0.01)
Venaxis slammed after FDA rejection
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 12:12PM CST
APPY: 0.45 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:47AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), SILC: 46.99 (+0.90), GNCA: 8.93 (-0.07), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), LRN: 16.56 (-0.06), SR: 1.25 (+0.08), DSKY: 11.99 (+0.14), GENE: 8.04 (+1.90), SMLR: 4.54 (+0.20), PFMT: 6.02 (-0.02), QCOM: 70.88 (+0.49), PSTR: 4.63 (+0.14), ENTL: 21.99 (+0.56), ATTU: 9.93 (+0.05), CTP: 6.53 (+0.13), LENS: 6.00 (-0.67), RCON: 2.11 (+0.15)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Venaxis, Inc. - APPY
PR Newswire - Thu Jan 29, 10:27AM CST
Pomerantz LLP is investigating claims on behalf of investors of Venaxis, Inc. ("Venaxis" or the "Company" (NASDAQ: APPY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
APPY: 0.45 (-0.01)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Venaxis, Inc.
PR Newswire - Thu Jan 29, 9:49AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Venaxis, Inc. ("Venaxis" or the "Company" (NasdaqCM: APPY -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
APPY: 0.45 (-0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
Venaxis Receives FDA "Not Substantially Equivalent" Response on APPY1 510(k) Submission
PR Newswire - Thu Jan 29, 5:25AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced the United States Food and Drug Administration ("FDA" has determined that the APPY1 Test does not meet the criteria for substantial equivalence based upon data and information submitted by Venaxis in its 510(k) submission.
APPY: 0.45 (-0.01)
Venaxis, Inc. to Present at Biotech Showcase(TM) 2015
PR Newswire - Tue Jan 06, 3:10PM CST
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1® Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will be presenting at the Biotech Showcase(TM) 2015, being held January 12-14, 2015, at the Parc 55 Wyndham Union Square Hotel in San Francisco, California.
APPY: 0.45 (-0.01)
Venaxis Business Update
PR Newswire - Thu Feb 12, 8:00AM CST
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1® Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced that the Company will host an investor conference call to discuss business matters, including the recent FDA "Not Substantially Equivalent" response, on February 13, 2015, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 0.45 (-0.01)
INVESTOR ALERT: Investigation on Behalf of Investors of Venaxis, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Feb 10, 6:02PM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. ("Venaxis" or the "Company"
(NASDAQ:APPY) concerning possible violations of federal securities laws. The investigation is focused on the Company's operations and financial prospects. APPY: 0.45 (-0.01)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Venaxis, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Feb 10, 12:43PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq: APPY) securities during the period between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until April 3, 2015 to seek appointment as lead plaintiff. APPY: 0.45 (-0.01)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Mon Feb 09, 8:11AM CST
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
XLS: 24.15 (+0.04), ADVS: 44.18 (+0.20), APPY: 0.45 (-0.01), MOV: 25.26 (-0.17), ENTR: 2.92 (unch), HLSS: 16.15 (-0.14), BABA: 89.05 (+1.95)
APPY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Venaxis, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of April 3, 2015 -- APPY
GlobeNewswire - Wed Feb 04, 1:16PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq:APPY) securities between March 13, 2014 and January 28, 2015. APPY: 0.45 (-0.01)
Robbins Arroyo LLP: Venaxis, Inc. (APPY) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Tue Feb 03, 7:18PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Venaxis, Inc. (Nasdaq:APPY) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Colorado. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between March 13, 2014 and January 28, 2015. Venaxis develops and commercializes products for unmet diagnostic and therapeutic needs.
APPY: 0.45 (-0.01)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in Venaxis, Inc. (APPY) to Contact the Firm
Marketwired - Tue Feb 03, 3:00PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Venaxis, Inc. ("Venaxis" or the "Company"
(NASDAQ: APPY) of the April 3, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Venaxis and certain officers of the Company. APPY: 0.45 (-0.01)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Venaxis, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- APPY
GlobeNewswire - Tue Feb 03, 12:53PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq:APPY) securities during the period between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until April 3, 2015 to seek appointment as lead plaintiff. APPY: 0.45 (-0.01)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Venaxis, Inc. and Certain Officers -- APPY
GlobeNewswire - Mon Feb 02, 6:45PM CST
Pomerantz LLP has filed a class action lawsuit against Venaxis, Inc. ("Venaxis" or the "Company"
(Nasdaq:APPY) and certain of its officers. The class action, filed in United States District Court, The District of Colorado, and docketed under 15-cv-00222, is on behalf of a class consisting of all persons or entities who purchased Venaxis securities between March 13, 2014 and January 28, 2015, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . APPY: 0.45 (-0.01)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 29, 5:14PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), PSTI: 2.91 (+0.01), APPY: 0.45 (-0.01), NVC.TO: 11.27 (-0.23), GEVO: 0.23 (+0.03), PSTB: 6.94 (+0.04), OVLY: 10.65 (-0.05), PFMT: 6.02 (-0.02), BWINB: 23.41 (+0.01), AMIC: 10.75 (-0.10), APRI: 1.84 (-0.08), BWINA: 23.45 (-0.79), INOD: 2.78 (-0.02), XNCR: 15.47 (-0.22), FBSS: 17.59 (-0.11), NVCN: 9.08 (-0.17)
INVESTOR ALERT: Investigation of Venaxis, Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Thu Jan 29, 3:35PM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. ("Venaxis" or the "Company"
(NASDAQ:APPY) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Venaxis concerning the Company's operations and financial prospects. APPY: 0.45 (-0.01)
Venaxis slammed after FDA rejection
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 12:12PM CST
APPY: 0.45 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:47AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), SILC: 46.99 (+0.90), GNCA: 8.93 (-0.07), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), LRN: 16.56 (-0.06), SR: 1.25 (+0.08), DSKY: 11.99 (+0.14), GENE: 8.04 (+1.90), SMLR: 4.54 (+0.20), PFMT: 6.02 (-0.02), QCOM: 70.88 (+0.49), PSTR: 4.63 (+0.14), ENTL: 21.99 (+0.56), ATTU: 9.93 (+0.05), CTP: 6.53 (+0.13), LENS: 6.00 (-0.67), RCON: 2.11 (+0.15)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Venaxis, Inc. - APPY
PR Newswire - Thu Jan 29, 10:27AM CST
Pomerantz LLP is investigating claims on behalf of investors of Venaxis, Inc. ("Venaxis" or the "Company"
(NASDAQ: APPY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. APPY: 0.45 (-0.01)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Venaxis, Inc.
PR Newswire - Thu Jan 29, 9:49AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Venaxis, Inc. ("Venaxis" or the "Company"
(NasdaqCM: APPY -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. APPY: 0.45 (-0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
Venaxis Receives FDA "Not Substantially Equivalent" Response on APPY1 510(k) Submission
PR Newswire - Thu Jan 29, 5:25AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced the United States Food and Drug Administration ("FDA"
has determined that the APPY1 Test does not meet the criteria for substantial equivalence based upon data and information submitted by Venaxis in its 510(k) submission. APPY: 0.45 (-0.01)
Venaxis, Inc. to Present at Biotech Showcase(TM) 2015
PR Newswire - Tue Jan 06, 3:10PM CST
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1® Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will be presenting at the Biotech Showcase(TM) 2015, being held January 12-14, 2015, at the Parc 55 Wyndham Union Square Hotel in San Francisco, California.
APPY: 0.45 (-0.01)
